SVB Leerink Starts Trevi Therapeutics (TRVI) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mailGet Alerts TRVI Hot Sheet
Price: $12.93 -1.97%
Rating Summary:
12 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 21 | New: 69
Rating Summary:
12 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 21 | New: 69
Join SI Premium – FREE
SVB Leerink analyst Ami Fadia initiates coverage on Trevi Therapeutics (NASDAQ: TRVI) with a Outperform rating and a price target of $14.00.
For an analyst ratings summary and ratings history on Trevi Therapeutics click here. For more ratings news on Trevi Therapeutics click here.
Shares of Trevi Therapeutics closed at $9.99 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Macquarie Starts Otsuka Holdings Co Ltd. (4578:JP) (OTSKY) at Underperform
- Barclays Starts Eastman Chemical (EMN) at Equalweight
- Barclays Starts Quintiles (Q) at Overweight
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
